Phase 4 Glaucoma Trial, Recruiting NCT05344274 Sponsor: University of Maryland, Baltimore Condition: Glaucoma
Back to Glaucoma

Phase 4 Glaucoma Trial, Recruiting

NCT05344274
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People whose eye examination shows an open drainage angle (a specific measurement of eye structure graded 3 or 4 on the Shaffer classification scale)
  • People whose glasses or contact lens prescription falls between +3.00 and -8.00 diopters
  • People whose best vision with glasses or contacts is 20/25 or better
  • People who fit into one of three groups: (1) those with early-stage glaucoma showing vision field changes limited to one half of the visual field, who are able to stop glaucoma medications for four weeks; (2) those with early signs of glaucoma damage to the optic nerve but no confirmed vision field loss yet; or (3) healthy control participants with no family history of glaucoma, normal eye scan results, normal visual fields confirmed by a glaucoma specialist, and a small cup-to-disc ratio as assessed by a glaucoma specialist

Who may not be able to join:

  • People with corneal problems or other eye conditions that prevent reliable eye pressure measurements
  • People with a retinal disease that affects the nerve fiber layer of the retina, such as vitreomacular traction, as determined by a glaucoma specialist
  • People who have a type of glaucoma caused by another condition (called secondary glaucoma)
  • People who have had eye surgery in the past, other than straightforward cataract surgery or a specific laser eye pressure procedure (laser trabeculoplasty)
  • People for whom stopping glaucoma medications for four weeks would not be safe
  • People whose eye movement or inability to focus makes it impossible to obtain clear eye scan images
  • People with unreliable visual field test results
  • People who have smoked at any point in the past six months
  • People with a cataract graded at level 2 or higher on a standard lens clarity scale
  • People with a diagnosis of diabetes, high blood pressure, or another known blood vessel disorder such as vasculitis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: (410) 328-5929

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
23 May 2022
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Autoregulation of retinal blood flow

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov